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Millions of scientific papers are produced each year and the scientific literature is
continuing to grow at a head-spinning speed. Thus, massive scientific knowledge exists in solid
text, but all these publications make it difficult, if not impossible, for researchers to keep in up
to date with discoveries, even within a narrow scientific area. This massive amount of
information also makes it difficult to find implicit and hidden connections, relationships, and
dependencies within the information that may guide the direction of future research or lead to
valuable new insights. So, there is a need for algorithms or models that can scan the text of
millions of papers to uncover new scientific knowledge and search for hidden connections
within this knowledge. For computer algorithms, to utilize this resource, it should be converted
in terms of numbers and represent the words in some mathematical form. This is where artificial
intelligence and machine learning can help. Advanced algorithms in machine learning and
natural language processing can be used to make large databases more useful and easier to
handle by both researchers and clinicians. We used Word2Vec for our implementation and
trained many unsupervised word-embedding models on different data sets in materials science
and in the medical field to extract hidden knowledge, relations, and interactions based on words
that appear in similar contexts in the text while often having similar meanings. So far, we have
adopted three main models. The first is trained within additive manufacturing (AM), targeting
the powder bed fusion (PBF) processes, such as selective laser sintering (SLS), selective laser
melting (SLM), and direct metal laser sintering (DMLS), with the goal of extracting new
knowledge to improve AM processes and address material properties depending on the process

used. Other properties inherent to the materials, such as the giant magnetocaloric effect, are
also addressed in a specific model. The second model is trained within COVID-19 drugs
literature to address what insights can be obtained on candidate drugs to treat COVID-19.
Finally, the third model is trained within COVID-19 vaccine literature to predict good
candidate vaccines. We thus demonstrate how word embeddings can help extract hidden
knowledge from the published literature in very distinct areas of research.
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CHAPTER 1
INTRODUCTION

1.1 Background and Context
Machine learning approaches are usually divided into three categories: supervised, unsupervised, and reinforcement learning. Supervised learning deals with labeled data, data that
contains both the inputs and the desired outputs, to train the model. It uses linear regression,
neural networks, nearest neighbor, or naive Bayes algorithms to predict or classify data.
Reinforcement learning allows machines or software agents to automatically decide the
required behavior within a specific situation to maximize its performance. Using Q-Learning,
temporal difference (TD), or deep adversarial networks, reinforcement learning algorithms can
be applied to robotic hands, computer-played board games, and self-driving cars. Unsupervised
learning is a machine learning technique that allows the model to work on its own to find
structure and discover patterns and information that were previously undetected, without the
need to supervise the model. It mainly deals with unlabeled data as input [1]. Clustering and
association are two types of unsupervised learning. The association rules establish relations
among data objects inside large databases, whereas clustering splits the dataset into groups
based on their similarities.
The word embedding technique is one of the most important, versatile examples of
unsupervised learning models, leading to a type of language modeling or word representation
that allows words with similar meanings to be understood by machine learning algorithms [2].
As a representation of words obtained from an unlabeled large corpus, by embedding both
semantic and syntactic meanings, word embedding can be represented as:

V

ℝD: 𝑤
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𝑤

mapping a word 𝑤 from a vocabulary V to a real-valued vector in an embedding space of
dimension D [3]. To compute the similarities between vectors in the embedding space, the
cosine similarity function can be used, which is defined as

similarity(w1, w2) =

w1. w2
║w1║║w2║

According to this function, the nearest neighbors of a word 𝑤 are given as a list of words
vϵV\{𝑤}, sorted in descending order [3].
Word embedding is an important method commonly used in the tasks of modern natural
language processing (NLP), such as semantic analysis [4], retrieval of information [5],
dependency parsing [6] [7] [8], query answering [9] [10], and computer translation [9] [11]
[12]. In these techniques, individual words are represented as real-valued vectors, often
comprising tens or hundreds of dimensions, in a predefined vector space. Each word is mapped
to one vector. The vector values are learned using an approach that resembles a neural network,
and, hence, the technique is often lumped into the field of deep learning. The word-embedding
methods vary and can be grouped into different categories. For example, models can be
classified as either paradigmatic or syntagmatic models, based on the word distribution
information [13] [14]. The most important aspect of the syntagmatic model is that words cooccur in the text region, whereas for the paradigmatic model, it is a similar context that matters.
Another grouping that is dependent on how the word embedding is generated divides models
into two classes: matrix factorization and sliding-window sampling. The first method is based
on the word co-occurrence matrix, where word embeddings are obtained from a matrix
decomposition. In sliding-window sampling, data sampled from sliding windows are used to
predict the context word [15]. Word embeddings have many important applications, such as
idiomaticity analysis, sentiment analysis, syntax analysis, speech (POS) tagging, named entity
2

recognition, as well as textual entailment [16]. Various word-embedding models are available,
such as Word2Vec, GloVe, and FastText.
The Word2Vec method is based on a shallow neural network with two layers, which
takes a large corpus of text as its input and produces a vector space, typically of several hundred
dimensions, with remarkable linear relationships called analogies. These allow for math
operations, such as vec(“king”) - vec(“man”) + vec(“woman”) ≈ vec(“queen”) [17]. As an
unsupervised learning technique, and a machine learning algorithm used to draw inferences
from datasets consisting of input data without labeled responses, it comprises two techniques:
CBOW (Continuous Bag of Words) and Skip-gram. CBOW predicts the probability of a word
given a context, while Skip-gram predicts the context given a word. These machine learning
models have great benefits and a significant impact in many areas of science and technology,
including medical research and materials science.
1.1.1 COVID-19 Drugs
The increase in knowledge and understanding of diseases and drugs is associated with
a growth in information. The resulting big data is ready to deliver the benefits of the application
of machine learning (ML) in diagnosis, prognosis, and drug development. AI and machine
learning models can change drug discovery radically by extracting hidden patterns, structures,
relations, and evidence from biomedical data. Pharmaceutical companies have used AI for drug
discovery and development.
At a time when COVID-19 patients flood hospitals worldwide, physicians are searching
for effective antiviral therapies to save lives. However, there is still a lack of proven effective
medications against COVID-19. Multiple vaccine trials and treatments are underway, yet they
need more time and testing. Furthermore, the SARS-CoV-2 virus that causes COVID-19
appears to affect various animals in different ways (with respect to infection and spreading),
which limits preclinical animal studies. So, one of the many major challenges of the pandemic
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has been to find effective treatments for the virus. The rapid spread of coronavirus has created
an immediate need for comprehensive therapies, which is a massive undertaking for scientists
and drug developers.
Since word embedding in machine learning could speed the research and open further
options by detecting existing drugs that could help fight COVID-19, we trained an
unsupervised learning model using the Word2Vec algorithm to capture latent knowledge about
COVID-19 drugs from the most recent literature, while focusing on the keywords: drugs,
biomedical, medication, antibodies, immunity, immunology, and vaccines. Depending on the
co-occurrence of the words, since words that occur together tend to have a similar context, we
used approved drugs, such as remdesivir, or most promising drugs, such as avigan, atazanavir,
dexamethasone, and REGN-COV2, as seeds to our model to find the most similar drugs. As a
result, we suggest some possible candidate drugs for clinical investigation or support other ones
in different testing phases for approval, according to their high similarity with the currently
approved and most promising treatments.
1.1.2 COVID-19 Vaccine
In order to address the COVID-19 pandemic by limiting transmission, an intense global
concerns the development of a safe and effective vaccine, which generally requires several
years of pre-clinical and clinical stages of evaluation, as well as strict regulatory approvals.
However, because of the unprecedented impact of COVID-19 worldwide, the development and
testing of new vaccines have been accelerated. There are currently some authorized, not yet
approved, vaccines to fight COVID-19, besides other ones in clinical evaluation or in a preclinical stage, and many more being researched. Vaccine discovery methods have been costly,
and it may take many years to develop an appropriate vaccine against a specified pathogen. In
the COVID-19 case, vaccines are essential in reducing morbidity and mortality, especially
since the virus establishes itself in the population. Thus, the development of a new vaccine
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should be accelerated to save lives. When most people in a community are vaccinated against
a disease, the ability of the pathogen to spread is limited, which also provides indirect
protection to people who cannot be vaccinated. Machine learning can accelerate the discovery
of effective vaccines or suggest components of a vaccine after understanding the viral protein
structure and assist medical researchers scouring tens of thousands of related scientific papers
[17][18].
1.1.3 Materials Science
Materials science focuses on the relationship between the structure, operation,
characteristics, and applications of materials. Current material science research involves many
“trial-and-error methods,” depending on the experience that guides a large number of
experiments, with a limited number of computer simulations and calculations. This
conventional method of studying materials is unreliable and consumes time, manpower,
materials, and ﬁnancial resources [19]. Therefore, finding a new efficient research method is
necessary to accelerate innovation. Machine learning could speed up the process by
constructing models that learn rules from datasets to effectively predict required properties of
materials, optimize the process parameters, obtain the hidden relationships among various
variables, guide the chemical synthesis route, and improve current material characterization
methods [20].
In materials science, additive manufacturing (AM) is an advanced type of
manufacturing technique that fabricates parts. It is the process of creating a 3D object through
a computer-aided-design (CAD) method by building it layer by layer. Several sectors are now
taking advantage of fabricating complex structures using AM technologies to increase
functionality, light-weighting, and part number reduction. AM is being used to fabricate enduse products in aircraft, custom parts (e.g., classic car parts, surgical tools), dental restorations,
medical implants, automobiles, handling and robotics, and even fashion products [21].
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Specific methods can be implemented in additive manufacturing based on different
needs to utilize different deposition techniques. Some of these melt the materials and some
change the materials into semisolid forms or powders. According to the different heating
sources used to change the material states, such as lasers and resistance heaters, additive
manufacturing can be divided into seven different processes [22]: vat photopolymerization
[23], material jetting, binder jetting, material extrusion, powder bed fusion, sheet lamination,
and direct energy deposition [24].
In powder bed fusion (PBF), thermal energy is used, typically in the form of a laser or
electron beam. Because of its low-cost quality, this process has widely grown in the last few
years and attracted the interest of researchers. PBF also allows for different materials, including
metals, plastics, glass, and alloys. Since the powder used in the process can be recycled to
produce more parts, recycling is one of the best qualities of PBF [25].
Selective laser sintering (SLS), selective laser melting (SLM), and direct metal laser
sintering (DMLS) [24][26] are common versions of powder bed fusion for fabricating metal
parts.
SLS is a process of combining powder material (e.g., nylon, thermoplastic, or
polystyrene) to build a solid piece layer by layer using heat and pressure, performed with the
help of a laser beam. SLS is ideal for biomedical uses, such as prosthetics, pre-surgical
planning, and bone scaffolds for tissue engineering [27][28].
SLM is a process that fabricates 3D products layer by layer using high-energy laser
beams on a powder bed, where the powder is melted rather than sintered. SLM can process
different materials, such as polymers, engineering plastics, and ceramic and metal oxide
materials. Furthermore, among all AM processes, SLM is the fastest and is able to fabricate
multiple parts in one round [29].
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Direct metal laser sintering (DMLS) is also a layer-by-layer, laser-based AM technique,
in which the product is developed with the use of metal powders. Basically, the machine
fabricates the object on a movable platform by applying incremental layers of the pattern
material, with an equal thickness of approximately 0.1 mm [29]. All processes continue, layer
by layer, until the object is fabricated completely.
In PBF techniques, process and product development are based on a few factors, such
as alloy chemistries, powder characteristics, powder bed processes and beam, powder
interactions, and material properties and performance. The wide range of materials that can
potentially be processed using PBF is one of the main advantages of PBF techniques.
Theoretically, any material that can be melted and resolidified can be processed with PBF; but,
in practice, this is not the case. The main materials and alloys used in PBF processes are
aluminum, tool steels, titanium, stainless steel, refractory, and super alloys [25].
However, PBF has its challenges, including high material costs; slow speeds; laborious
post-processing requirements; and restrictions on materials compatibility. In addition, a variety
of defects limits the process in terms of repeatability, precision, and resulting mechanical
properties [30], such as porosity, cracks, and residual stresses problems. These challenges can
be improved by more research into how the materials interact when being fused together. Also,
if more people understand the material properties and how they interact in specific heat (such
as lasers) and for different alloys, then there is a better chance to understand how to avoid these
defects and make this process more efficient. The world is still waiting for materials that enable
the technology to fulfill its true potential.
As an example for these materials and within our area of interest are the materials with
compounds exhibiting a giant magnetocaloric effect (GMCE). By applying/removing a
magnetic field, the isothermal entropy or the adiabatic temperature will change. A sharp change
in magnetization associated with the structural transformation from the high-temperature
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austenite phase to the low-temperature martensite phase of lower crystallographic symmetry
results in large GMCE [31]. Simply, it is the ability of some magnetic materials to heat up
when they are magnetized and cool down when are demagnetized in a thermodynamic cycle.
Ni-Mn-based Heusler alloys are one of the materials that exhibit GMCE materials. Heusler
alloys (HAs) are materials of enormous interest due to their multifunctional properties
including shape memory, magnetoresistance (MR), thermoelectric effect, half-metallicity, spin
filtering, and spin injection [31].
To lend a hand in facing these challenges, we trained several unsupervised wordembedding models using Word2Vec on literature involving powder bed fusion (PBF) as the
AM process, trying to determine the main additive manufacturing parameters that affect the
alloy properties, after the composition is already known or determined. Furthermore, using
these models, we intend to search for new high-performance materials or properties that are
similar to the ones currently known and could be used to improve AM.
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CHAPTER 2
THE PROBLEM ADDRESSED IN THIS DISSERTATION
2.1 Problem Statement
The vast majority of scientific knowledge is published in articles that provide useful
knowledge of the interactions and relationships between data objects as viewed by the authors.
However, it is difficult to interpret this knowledge either by ordinary machine learning
approaches or advanced statistical analysis. For its leverage, that knowledge from the published
literature is represented using vectors of words or word embeddings. Without human labeling
or any explicit insertion of pre-knowledge, these embeddings can capture hidden or unknown
relations existing within very different fields, such as materials science or COVID-19 drug and
vaccine research.
2.2 Research Questions
How can word embeddings, using Word2Vec, help to extract hidden knowledge from
the published literature?
What candidate drugs can be obtained from word embeddings using Word2Vec
algorithms to treat COVID-19 (the study and results reported in [32])?
What candidate vaccines can be obtained from word embeddings using Word2Vec
algorithms to reduce COVID-19 cases (the study and results reported in [33])?
What new knowledge on materials and properties, which are similar to those of known
materials and properties, can be extracted to improve AM processes?
2.3 Relevance and Importance of the Research
Our COVID-19 model may suggest possible candidate drugs or vaccines for clinical
investigation and support other ones in different testing phases for approval, according to their
high similarity with currently approved and most promising treatments. We also hope that our
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AM models, particularly on SLS, SLM, and DMLS, could add some improvements to AM
processes.
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CHAPTER 3
LITERATURE REVIEW
3.1 COVID-19 Drugs
3.1.1 Drug Repurposing
Drug repurposing or repositioning is a strategy that uses previously approved drugs to
treat newly emerging and challenging diseases, including COVID-19, by extracting hidden
patterns and evidence from biomedical data [34]. This technique reduces development
timelines and costs, since the safety of these drugs has already been tested in clinical trials for
other applications. The probability of failure is lower because, in preclinical models, the
repurposed drug has already been shown to be reasonably effective, and subsequent efficacy
tests are less likely to fail at least from a safety point of view if the early-stage tests have been
completed [35]. Some successful drug repurposing examples are Zidovudine in 1987 to treat
HIV/AIDS, which was originally used to treat cancer, and the repurposing of aspirin in 2015
to treat colorectal cancer, even though its regular use had been for analgesia [35].
3.1.2 Drug Repurposing Using Machine Learning
Machine learning is creating a paradigm shift in medicine, starting with research and
ending in clinical applications. A variety of machine learning methods are showing their utility
for drug discovery and development, such as naive Bayesian, support vector machines, and,
more recently, deep neural networks.
Many works discuss the role of machine learning models in precision medicine. Beck
et al. [40] developed a hybrid CNN and RNN model called Molecule Transformer-Drug Target
Interaction (MT-DTI), a pre-trained deep learning-based drug-target interaction model to
predict whether any commercially available antiviral drugs could work for SARS-CoV-2. The
authors identified several known antiviral drugs, such as atazanavir, remdesivir, efavirenz,
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ritonavir, and dolutegravir, for the potential treatment of SARS-CoV-2 infection. Furthermore,
they suggested considering the list of antiviral drugs identified by the MT-DTI model and also
found that several antiviral agents, such as Kaletra (lopinavir/ritonavir), could be used for the
treatment. According to the associated inhibitory potency, their result showed that the best
chemical compound is atazanavir, which is an antiretroviral medication used to treat and
prevent human immunodeficiency virus (HIV) infection, with an inhibitory potency of 94.94
nM against the SARS-CoV-2 3C-like proteinase; remdesivir (113.13 nM) came next, then
efavirenz (199.17 nM), ritonavir (204.05 nM), and dolutegravir (336.91 nM). In Beck et. al’s
prediction, lopinavir, ritonavir, and darunavir may also bind to the replication complex
components of SARS-CoV-2 with an inhibitory potency with Kd < 1000 nM, in addition to
targeting viral proteinases [40].
Another machine learning technique used to discover candidate drugs for SARS-CoV2 is graph representation learning. This deep-learning technique is used to predict new links
and relations between existing approved drugs. The graph contains relationships between
different kinds of medical entities (e.g., diseases, drugs, and proteins). Gysi and his team [36]
used this technique to develop a model that presented a SARS-CoV-2 case study with 81
potential repurposing candidates identified. According to their prediction, the virus can be
found in different tissues, such as the reproductive system, and brain regions. They developed
three network-based drug repurposing strategies, relying on their prediction and depending on
network proximity, diffusion, and AI-based metrics. Based on their likely efficacy for COVID19 patients, in addition to aggregating predictions, their strategies rank all approved drugs.
Ritonavir, isoniazid, troleandomycin, cilostazol, chloroquine, rifabutin, and flutamide are the
first seven highest ranked COVID-19 candidate drugs.
Another team worked with graph representation learning to construct a comprehensive
COVID-19 knowledge graph (named CoV-KGE), using a large scientific corpus of 24 million
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PubMed publications to create a knowledge graph with 15 million edges across 39 types of
relationships connecting pathways, drugs, genes, diseases, proteins, and expressions of genes
and proteins. To build this deep-learning methodology, Zeng et al. [37] used Amazon Web
Services’ computing resources and graph representation learning techniques. As a result, the
team identified 41 repurposed drug candidates (including dexamethasone and melatonin) for
COVID-19 treatment distributed over three categories, including anti-inflammatory agents,
selective estrogen receptor modulators (SERMs), and antiparasitics. For validation, they used
the ongoing COVID-19 trial data set as a validation set. CoV-KGE showed high performance
in identifying COVID-19 repurposable drugs, as indicated by its large AUROC metric value
(AUROC = 0.85). AUROC, the area under the receiver operating characteristic, is a
performance metric that can be used to evaluate classification models [37].
Kuusisto and his team [38] introduced an unsupervised learning method using a wordembedding mining approach to find out candidate treatments for SARS-CoV-2. They used the
BioWordVec5 model [39], the most recent prebuilt biomedical word embedding available at
the time, which performed well on several benchmark tasks. Given that SARS-CoV-2 is a strain
of SARS-CoV they used SARS as an approximation reference to SARS-CoV-2 or COVID-19
because BioWordVec was published before SARS-CoV-2 was discovered and has no reference
to SARS-CoV-2 or COVID-19 in its vocabulary. To find a vector representation for treatments,
they used the analogy approach [17]. Taking advantage of word-embedding structure and its
ability to carry semantic meaning, they used three separate drug-to-disease pairs as a seed
treatment for the analogies: metformin to diabetes, benazepril to hypertension, and albuterol to
asthma. The drug names were extracted from the FDA’s approved drug database [41]. To
validate their work, they used these seed drug-disease pairs as analogies to find drugs for
Alzheimer’s, allergies, and cancer. All drugs resulting from each analogy for each validation
disease were the drugs with primary indications for this disease (Alzheimer’s, allergies, and
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cancer) or a similar disease from the same family. Then they used SARS as the query disease
and marked every drug that has either been suggested or is currently under investigation for
the treatment of SARS-CoV-2. Their results showed 22 of 50 drugs either suggested or under
investigation for treatment against SARS-CoV-2 from the metformin-diabetes analogy, 12 of
50 hits from benazepril-hypertension analogy, and 8 from the albuterol-asthma analogy.
Amantadine, rimantadine, zanamivir, oseltamivir are some hits common to all analogies.
3.2 COVID-19 Vaccines
3.2.1 Vaccine Development
A pathogen is a bacterium, virus, parasite, or fungus that can cause disease within the
body. Each pathogen has its unique subparts. One important factor is the antigen, which causes
the formation of antibodies. The antibodies produced in response to the pathogen’s antigen are
an important part of the immune system. Often, vaccines contain weakened or inactive parts of
a particular antigen that train the immune system to recognize and fight pathogens, which
greatly reduces the risk of infection. The immune system can safely recognize the pathogen
when it is encountered naturally; and by delivering an immunogen, a specific type of antigen
elicits an immune response [42].
To fight virus-infected cells, the host immune system produces antibodies on the
surface of B-cells or attacks the virus directly using T-cells. To assist T- and B-cells in attacking
and binding with invaders, the human leukocyte antigen (HLA) gene encodes MCH-I and
MCH-II proteins, which present epitopes as antigenic determinants [43].
To ensure the safety and efficiency of the new vaccine, many actions and steps are
taken, such as pre-clinical studies, Phase I clinical trials, Phase II clinical trials, Phase III
clinical trials, Phase IV post-marketing surveillance, and human challenge studies. In the preclinical studies, the vaccine is tested first in animal studies for efficacy and safety. Then in a
Phase I clinical trial, small groups of healthy adult volunteers receive the vaccine to test for
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safety. After that, in a Phase II clinical trial, people who have characteristics for whom the new
vaccine is intended are given the vaccine. The next step of testing the vaccine is by giving it to
thousands of people, which is a Phase III clinical trial. After the vaccine is approved and
licensed, many studies are conducted to learn the future effects of the vaccine in the population
in the long term [44].
Since the outbreak of the novel coronavirus, different machine learning approaches
have been used to predict potential effective vaccines.
3.2.2 Machine Learning and the Development of COVID-19 Vaccines
To accelerate the vaccine design process by predicting the design of a multi-epitope
vaccine for COVID-19, Zikun et al. [45] implemented a supervised deep-learning model
(DeepVacPred) in silico. From the available SARS-CoV-2 spike protein sequence, their model
was able to predict 26 candidate vaccine subunits, by combining the in silico
immunoinformatic and deep neural network strategies. In order to construct a multi-epitope
vaccine for the SARS-CoV-2 virus, they identified the top 11 from the 26. According to the
best 11 candidates, they suggested a 694aa (consisting of 694 amino acid residues) multiepitope vaccine that contains 16 B-cell epitopes, 82 CTL epitopes, and 89 HTL epitopes, as a
promising vaccine to fight the SARS-CoV-2 viral infection. They also concluded that the
designed vaccine can be used successfully with the recent RNA mutations of the virus by
investigating the SARS-CoV-2 mutations for RNA.
Since the T-cell and B-cell epitopes could be used to produce good vaccines, as well as
recognize neutralizing antibodies, Fast et al. [46] tried to identify 2019-nCoV T-cell and B-cell
epitopes based on viral protein antigen presentation and antibody binding properties, using
computational tools from structural biology and two supervised neural networks (MARIA, a
multimodal recurrent neural network [47] and NetMHCpan4, a trained neural network in [48]).
Their results show good antigen presentation scores for 405 potential viral peptides, for both
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human MHC-I and MHC-II alleles. Their models also identified two potential neutralizing Bcell epitopes close to the 2019-nCoV spike protein receptor-binding domain (440-460 and 494506). They also concluded that the spike protein for the SARS-CoV-2 virus could be a potential
vaccine candidate. This conclusion was the result of their analysis of mutation profiles of 68
viral genomes spread through four continents that showed no mutations are present near the
spike protein receptor-binding domain, and 96 coding-change mutations occurred only in
regions with good MHC-I presentation scores [46].
By using the same method, the recurrent neural networks (RNN), and a training set
consisting of alpha, beta, gamma, and delta coronavirus spike sequences, Crossman simulated
the spike protein sequences of coronaviruses for the previously known sequences and tested
their characteristics. This simulation could help in the development of vaccine design to predict
alternative possible spike sequences that could arise in the future [49].
In another study that introduces a computational framework from several computational
approaches, such as reverse vaccinology and immunoinformatics tools with deep learning,
Abbasi et al. [50] predicted a potentially suitable protein vaccine candidate against SARSCoV-2. Reverse vaccinology uses the expressed genomic sequences to find new potential
vaccines, whereas immunoinformatics tools, such as PSORTb, FungalRV, SignalP, TargetP,
IEDB, BLASTp, ProtParam, Vaxijen, etc., were modified to classify proteins into positive and
negative datasets. As a result, one protein (Spike S–Surface Glycoprotein with accession no.
QHD43416.1) was shortlisted as a potential vaccine candidate out of the 10 proteins of SARSCoV-2. Out of 41 B-cell epitope sequences that were predicted using BcePred, only 15 peptides
were identified to be highly antigenic as specified by the Vaxijen server, where a peptide
“DLCFTNVY” is predicted as the highest-ranking peptide. For T-cell epitopes, they consider
peptides with a 100% conservancy rate, so 45 epitopes were identified by the ProPred-I tool to
be conserved out of the 46 predicted MHC class-I binding epitopes, where KIADYNYKL was
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found with the highest antigenicity score and 90 out of 94 MHC- II allele binding T-cell
epitopes predicted by the ProPred tool with VKNKCVNFN as the highest antigenicity score.
3.3 Machine Learning in Materials Science
Due to the enormous numbers of controllable and uncontrollable parameters, the large
size of the data acquired, and the difficulties encountered in analyzing it, processing the data
in the AM process is a difficult task. Also, manually detecting the defects in AM processes is
time-consuming and laborious work. Therefore, there is a need for applying machine learning
(ML) techniques for processing the data and detecting defects.
3.3.1 Optimizing AM Process Parameters
Traditionally, to additively manufacture new materials, simulation methods and the
design of experiments are used to implement process parameter development and optimization.
The physically-based simulation can reveal the underlying mechanism for the formation of
specific features during processing. However, it may suffer from discrepancies with
experimental results due to simplified assumptions. On the other hand, the design of experiment
approaches involves trial-and-error, which is time-consuming and costly for AM. Therefore,
to address these challenges in the process optimization of metal AM, many researchers have
explored the feasibility of introducing ML approaches [51].
To predict some properties, such as the high cycle fatigue life of laser powder bed fusion
of stainless steel 316, Zhang et al. examined the use of a neuro-fuzzy-based machine learning
method. For simulating a complex nonlinear input-output environment, they prepared a dataset
that consists of fatigue life data for samples with different processing conditions, such as scan
speed, laser power, and layer thickness; post-processing treatments, such as annealing and hot
isostatic pressing; and cyclic stresses. They developed two models for the processing/postprocessing parameters and tensile properties. The models showed a good prediction accuracy
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against the test data, even with the diverse fatigue and fracture properties. The team suggested
that these models could be used concurrently, for quality assurance at the manufacturing stage
and property assessment stage [52].
In another prediction, Shen et al. developed an artificial neural network (ANN)
approach for density prediction of SLS parts. Their ANN is a two-layer supervised neural
network supplied with SLS process parameters, such as laser power, scan speed, scan spacing,
and layer thickness. To collect experimental training and test datasets, an orthogonal
experimental method was employed. They concluded that, by applying the ANN approach, the
density prediction of SLS parts is rather accurate. Their method does not need to know the
precise model, which is an outstanding advantage [53].
Wang et al. used a neural network combined with GA (Genetic Algorithm) techniques
to study SLS optimum process parameters, such as layer thickness (0.2 mm), interval time (1
s), laser power (18 W), scanning speed (1,800 mm/s), hatch spacing (0.12mm), work
surroundings temperature (93°C), and scanning mode (subarea and direction change scanning),
based on the minimum shrinkage ratio. These parameters were obtained by using the genetic
algorithm based on the neural network model, so that the part manufactured under the optimal
process parameters results in minimum shrinkage. The GA searched the global optimum with
reasonable speed for population size = 30. After applying the measurements five times under
the same condition layer, they found that the repeatability of the shrinkage ratio was good,
between 0.128% and 0.130%, depending on the part number [54].
3.3.2 Detecting Defects
ML has been successfully used in different defect detection scenarios during the AM
process. To detect the track defect and predict the printability of materials in SLM for the
application in a factory, Chen et al. introduced a neural network (NN) as a supervised machine
learning (ML) method. Their method helps in finding the better parameter combinations for
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intelligent defect-free printing. A 3D microscope inserted into the selective laser melting
method for in-situ measurement was used to track the process. As findings, they classified five
types of the printed single tracks according to the measured surface morphologies, and the
results were used as target outputs for the ML model. Then, for a quantitative evaluation of the
quality of the tracks, they used four evaluation indicators, which are correlated to the surface
morphology and important geometrical characteristics of the printed single tracks. Their
approach using a backpropagation neural network model successfully predicted the process
window for parameters, such as laser power and scan speed, for a TiB2 reinforced AlSi10Mg
composite. Furthermore, they confirmed the feasibility of the prediction model by experiment
[55].
In another work, Yadav et al. prepared a balanced labeled dataset (with an equal number
of “drift” and “no-drift” data points) for training a supervised Support Vector Machine (SVM)
classifier, as a classification algorithm that divides the dataset into multiple classes, to detect
the drift in the parts [56]. By drift they mean the non-uniformity that results in “hotspots” in
the melt pool signatures. These hotspots are the areas of the highest probability to generate real
defects in the part. In addition, they are an indication of drift; these are the areas where the
intensity of the signal is higher compared to the rest of the layer. To acquire the in-situ data, a
co-axial melt pool monitoring (MPM) system installed on a commercial SLM 280HL machine
was used without any additional hardware modifications. Specific geometries incorporating the
overheating and lack of fusion drift were printed by varying the volumetric energy density and
were used to test the trained algorithm. The trained SVM classifier was tested for the
overheating of samples and for lack of fusion, which results in internal porosity in the final part
and is a challenging detection task. As a result, their model was able to allocate 98.53% of data
points with the correct label—“drift” or “no-drift” [56].
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Gobert et al. [57] used in-situ layer-wise imaging with a digital single-lens reflex
camera to take images of each layer during the build process, under different lighting
conditions. They used these images as data for a supervised ML model, using binary
classification techniques, i.e., a linear support vector machine (SVM), for defect detection
during the L-PBF process. Computed Tomography (CT) scans were used to evaluate the
results. In CT scans, discontinuities, e.g., incomplete fusion, porosity, cracks, and inclusions,
were identified using automated analysis tools or manual inspection. After training the model,
the resulting accuracy of defect detection during the process was up to 85% [57].
Using a convolutional neural deep network, Baumgartl et al. could detect and identify
defects during printing processes with an average balanced accuracy of 96.80%. Their model
achieves fast compilation and training without the need for powerful hardware, even though it
is very small and light in computational costs. They used thermographic images for training
and testing. The images were taken in the printing process of H13 steel specimens, during insitu off-axis monitoring. For the network training of a geometrical shape, an uncritical defect
splatter and critical defect delamination were chosen. Also, the model could output a heatmap
to help in deciding the type and location of the error. Their model could be used for other defect
types, as well as for in-situ defect detection of L-PBF processes, because the model is based
on a single source of information, and there is no need to carry out additional evaluations using
expensive and time-consuming methods like X-ray or CT [58].
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CHAPTER 4
RESEARCH METHODS

4.1 Data Collection and Processing
4.1.1 COVID-19 Drugs Model
We obtained around 18,600 full-text papers and articles primarily focused on COVID19 in the years 2019 and 2020 from Science Direct at Elsevier. Through Science Direct
application programming interfaces (APIs) (https://dev.elsevier.com/), interactive APIs, and
with some Python (3.6) code [59] we performed the text-mining process. We searched the
Science Direct database using specific search terms as a first step in cleaning the data. These
terms combined “COVID-19 OR 2019-nCoV OR COVID19 OR nCoV-19 OR Sars-CoV-2”
with keywords, such as drugs, biomedical, medication, antibodies, immunity, immunology,
and vaccines.
4.1.2 COVID-19 Vaccines Model
From Science Direct at Elsevier, we obtained around 54,427 full-text published papers
and articles primarily focusing on COVID-19 in the years 2019, 2020, and 2021 (see Table 1).
In order to perform the text-mining process, we used Science Direct application programming
interfaces (APIs) (https://dev.elsevier.com/), interactive APIs, and some Python (3.6) code
[59]. We searched the Science Direct database using specific search terms as a first step in
cleaning the data. These terms combined “COVID-19 OR 2019-nCoV OR COVID19 OR
nCoV-19 OR Sars-CoV-2” with vaccines, biomedical, medication, antibodies, immunity,
immunology, and drugs.
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Table 1.
The Obtained COVID-19 Data from Science Direct in the Elsevier
2019

2020

2021

Drugs

99

4870

3475

Vaccines

110

7850

5115

Biomedical

32

1888

1469

Medication

21

4274

2685

Antibodies

104

4497

2931

Immunity

115

7462

4764

Immunology

35

1540

1091

Sum

516

32381

21530

Toltal

54427

4.1.3 AM Model
We obtained around 95,990 full-text papers and articles primarily focused on Ni-Mnbased alloys, SLM, SLS, DML in the years from 2012 to 2022 from Science Direct at
Elsevier (see Table 2).

Table 2.
The Obtained SLS, SLM, and DMLS Data from Science Direct at Elsevier
Year
2022
2021
2020
2019
2018
2017
2016
2015
2014
2013
2012
Total

Ni-Mnbased alloys
64
6800
6443
5574
4935
4422
3697
3697
3180
3045
2506
44363

SLM

SLS

DMLS

32
4076
4054
3368
2909
2222
1805
1459
1316
1173
968
23382

23
2313
2309
1947
1629
1234
1045
834
701
624
478
13137

19
2453
2331
2095
1820
1446
1278
1082
972
882
730
15108

22

Through

Science

Direct

application

programming

interfaces

(APIs)

(https://dev.elsevier.com/), interactive APIs, and some Python (3.6) code [59], we performed
the text mining process.
4.2 Cleaning Data
Extensive cleaning processes were needed to reduce the noise in the corpus, speed up
model training, and improve model efficiency. We deleted words with a length of more than
20 letters; usually, these words are URLs or descriptions related to the metadata. Then we
converted all uppercase characters in the corpus to lowercase, so COVID and covid will have
one vector. Finally, we deleted the stop words and punctuation from the corpus, so “vaccine”
and “vaccine,” will have one vector. We started with a data file of size 820 MB and obtained a
reduced file of size 600 MB for the COVID-19 drugs model and from a file of size 2.74 GB to
a reduced file of size 2 GB for COVID-19 vaccine. Finally, for the AM model, an initial data
file of size 6.58 GB yielded a reduced file of size 4.42GB.
4.3 Word2Vec Training
We used a combination of the Word2Vec implementation in genism [60] and the opensource code implemented by Vahe Tshitoyan et al. [61], with a few modifications to train our
models.
Several parameters that affect both training speed and efficiency are recognized by
Word2Vec. In our models, we only consider vocabulary that occurs more than five times
because words that appear in a billion-word corpus only once or twice or less than five times
are probably uninteresting typos and garbage. Furthermore, there is not enough knowledge to
include any practical training on those terms, so it is better to ignore them. The vector size, or
size of the embedding, in the models is 200. Larger size values need more data from training
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but can lead to better (more precise) models. Usually, fair vector size values are in the tens to
hundreds[61].
To speed up the training, we set the workers parameter to 16 workers, which relates to
the number of threads to employ while training. The models were trained using a 10th
generation Intel i7 processor that features 8 Cores and 16 Threads. Since Python contains
excellent built-in tools for both multiprocessing and threading, we adjusted the code for
Word2Vec to use multiple threads. In the gensim Word2Vec, the input stream of sentences is
chunked (fixed number of sentences,100 by default) into jobs that are sent to threads for
training [62]. Models use a skip-gram algorithm for the training with negative sampling loss.
With negative sampling, we randomly select just a small number of “negative” words (let’s say
n = 15) for which to update the weights. In this context, a “negative” word is one for which the
neural network should output a 0. Negative sampling decreases the computational burden of
the training process and increases the efficiency of the resulting word vectors by having each
training sample only modify a small percentage of the weights, rather than all of them [63]. It
was found that skip-gram with negative sampling loss (n = 15) performs best according to
Tshitoyan [61].
With respect to Google code [64], the author indicated that CBOW is faster, while Skipgram is slower, but the latter does a better job with infrequent words because Skip-gram seeks
the prediction of the context given a word instead of the prediction of a word given its context
like CBOW does. The window size was 8, which relates to the maximum distance within a
sentence between the actual and the predicted word. The initial learning rate was 0.01 and
would drop linearly to 0.0001 as training progressed in 30 epochs. The learning rate aims to
decide what proportion of the observed error should be used to change weights. The typical
range is between 1 and 10-6. The model will oscillate if the learning rate is set too high, and the
model will converge too slowly to a solution by setting it too low. A learning rate of 0.01
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usually works with most networks [65]. To optimize the computation, we use a hierarchical
SoftMax training algorithm, which employs a binary tree to represent all words in the
vocabulary [66]. We also trained a model with a different parameters combination according
to some other references. For example, we set the number of vector dimensions to 400 instead
of 200 [67], the window size of words to 9 instead of 8 [68], the negative samples to 5 instead
of 15 [68], and we used CBOW instead of skip-gram [17]. We performed some verification
and the results, for example in the similarities, were too far to be considered as similar words
to a specific queried word. In addition, several strange words and words without meaning
occurred as similar words. So we decided not to consider the model with these parameters

Table 3.
The Top 10 Similarities for COVID-19, Drugs, Fever, and Hygiene
Covid19

Drugs

Fever

Hygiene

covid_19

medications

dry_cough

Handwashing

disease

antiviral_drugs

fever_cough

hand_hygiene

sarscov2

repurposed_
drugs

shortness_breath

personal_hygiene

pandemic

Medicines

dyspnoea

good_hand_hygiene

coronavirus

antiinflammatory_
drugs

symptoms

hygiene_practices

2020

Treatments

malaise

Sanitation

patients

Repurposed

cough_shortness_
breath

preventive_measures

covid

antimalarial_
drugs

fever_fatigue

wear_mask

cases

drug_candidates

flulike_symptoms

Distancing

severe

existing_drugs

nonproductive_
cough

cough_etiquette
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CHAPTER 5
RESULTS AND DISCUSSION
5.1 COVID-19 Drugs Model
5.1.1 Verification
Some generally known words for COVID-19 and their top 10 similarities were used to
verify our model, CDVec. We chose covid19, drugs, fever, and hygiene since these and their
similarities are well-known. Similar words tend to occur together and will have a similar
context, and words with similar contexts end up with similar vectors. As preiously shown in
Table 3, the top 10 similar words for covid19 are covid_19, disease, sarscov2, pandemic,
coronavirus, 2020, patients, covid, cases, and severe. These words are often found in the same
context as covid19. The word drugs has medications, antiviral_drugs, repurposed_drugs,
medicines,

anti-inflammatory_drugs,

treatments,

repurposed,

antimalarial_drugs,

drug_candidates, and existing_drugs as similar words. On the other hand, the top 10 similar
words for fever are well-known and main symptoms for COVID-19. These words are
dry_cough,

fever_cough,

shortness_breath,

dyspnoea,

symptoms,

malaise,

cough_shortness_breath, fever_fatigue, flulike_symptoms, and nonproductive_cough. The top
10 similar words for the fourth word, hygiene, are handwashing, hand_hygiene,
personal_hygiene, good_hand_hygiene, hygiene_practices, sanitation, preventive_measures,
wear_mask, distancing, and cough_etiquette. These similarities are some of the most important
ways to protect against COVID- 19 and many other diseases.
5.1.2 Similarities for Some Drugs
The therapies currently under investigation include drugs that have been used to treat
autoimmune diseases, antiviral drugs, and antibodies from people who have recovered from
COVID-19.
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In this section, we discuss results for some current candidates for COVID-19 drugs that
are found in the published literature with their similarities.
Looking for drug similarities reveals more candidate drugs to be tested and other ones
to be excluded, or it may increase the chance for under-testing candidates. Without any explicit
insertion of prior chemical or structural knowledge about the drugs or COVID-19 treatments,
CDVec can find candidate drugs based on word co-occurrences. We divided the results into
the categories of antiviral drugs, anti-inflammatory drugs, and antibodies cocktail.
5.1.2.1 Antiviral Drugs
5.1.2.1.1 Remdesivir
The antiviral drug remdesivir (Veklury) was approved in October 2020 by the U.S.
Food and Drug Administration (FDA) to treat certain patients hospitalized with COVID-19.
Remdesivir is recommended for the treatment of COVID-19 in adults and pediatric patients
(12 years of age and older and weighing at least 40 kg) who need hospitalization [69]. However,
this approval does not include the entire patient population, and scientists are working hard to
develop other effective treatments. CDVec suggests lopinavir-ritonavir, favipiravir,
remdesivir_chloroquine, darunavir, lopinavir_ritonavir, hydroxychloroquine, and galidesivir
as top candidates with highest similarities as shown in Figure 1.
5.1.2.1.2 Avigan/Favipiravir
Since 2014, Avigan has been approved as an influenza antiviral drug for manufacturing and sale in Japan, as it selectively inhibits the RNA polymerase required for the viral
replication of influenza [70], and this is the basis for pursuing approval for treating COVID19. It has been approved, at least on an emergency basis, for COVID-19 by many nations, such
as Russia and India, and is on the way to being formally approved by other countries, such as
Japan.
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CDVec shows that

inhibitors_remdesivir_favipiravir, roseltamivir_umifenovir,

boceprevir, rimantadine_amantadine, avipiravir_un_dergone, zalcitabine, (favipiravir_
undergone), ribavirin_ remdesivir, and adefovir are the top similar drugs to Avigan, and that
may increase their chance to be used as COVID-19 treatments (Figure 2).

Figure 1. The Top 10 Similar Words for Remdesivir

Figure 2. The Top 10 Similar Words for Avigan
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5.1.2.1.3 Atazanavir
Atazanavir is a prescription drug that was originally approved by the FDA for the
treatment of HIV in adults and children from three months of age [71]. Atazanavir belongs to
the protease inhibitors class of medications and functions to decrease the amount of HIV in the
blood [72]. In a recent study [73], it was found that atazanavir inhibits SARS-CoV-2
replication, in Vero cells and a human pulmonary epithelial cell line, alone or in combination
with ritonavir (RTV). Atazanavir/ritonavir also weaken virus-induced enhancement of
interleukin 6 (IL-6) and tumor necrosis factor-alpha (TNF-α) levels, and the results clearly
suggest that atazanavir should be nominated among the repurposed drugs undergoing clinical
trials in the battle against COVID-19. Other studies suggest atazanavir according to the
associated inhibitory potency as the best chemical compound followed by remdesivir,
efavirenz, ritonavir, and dolutegravir for treating COVID-19. When CDVec obtains the similar
words for atazanavir, it finds the same order for remdesivir (with similarity = 0.594158) and
efavirenz (with similarity = 0.594158), then ritonavir (with similarity = 0.594398), but with
higher similarity for dolutegravir (with similarity = 0.654778).
On the other hand, CDVec indicates more drugs that are similar to atazanavir but with
similarities higher than the previous drugs, such that nelfinavir, ritonavir, cobicistat, tipranavir,
and saquinavir.
5.1.2.2 Anti-Inflammatory
5.1.2.2.1 Dexamethasone
Dexamethasone, a corticosteroid, is identical to a natural hormone formed by the
adrenal gland. When the body does not produce the natural hormone, it replaces it to relieve
inflammation, such as redness, swelling, pain, and heat; treat some cancer types; heal intestinal
disorders (e.g., colitis, severe allergies, and asthma); treat certain forms of arthritis and skin,
blood, kidney, eye, and thyroid diseases [74]. Dexamethasone has decreased mortality in
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patients diagnosed with COVID-19 by 28 days among those undergoing intrusive mechanical
ventilation or randomized oxygen on their own but not among those without any respiratory
assistance [75][76].

Figure 3. The Top 10 Similar Words for Dexamethasone

CDVec proposes the top similar words for dexamethasone as methylprednisolone,
corticosteroid, prednisolone, anakinra, bevacizumab, steroid, anti-inflammatory_drugs,
combination_lopinavirritonavir (see Figure 3). From these similarities, methylprednisolone,
anakinra, bevacizumab, and azithromycin_hydroxychloroquine are promising treatments, so
their presence in dexamethasone similarities increases their chances to be considered as future
treatments for COVID-19.
5.1.2.3 Antibody Cocktail
An antibody is a protein produced by immune cells in just the right shape and size to
bind to a certain foreign object, such as a virus or bacteria in the blood, at a particular point.
By entering the antibody, these invaders may be used to directly resist infection or they can be
labeled for immune cell death.
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5.1.2.3.1 REGN-COV2
The antibody cocktail in REGN-COV2 trials is a combination of two effective,
complementary, virus-neutralizing antibodies, monoclonal antibodies (REGN10933 and
REGN10987), that originates from a human survivor of COVID-19. Regeneron scientists
selected them after evaluating and investigating thousands of options. Each antibody binds to
the spike proteins on the virus to block the interaction between the virus and healthy cell, which
makes the binding less successful. According to the preclinical studies, REGN-COV2 reduced
the virus concentration and associated harm in the lungs [77]. We get many other antibody
candidates from our model with high similarities (80%). We obtain ty027, js016, brii196,
ctp59, brii198, scta01, 5_vector_expresses, humanized_igg1, nct04348877, and nct04344015
as the top 10 similar words to REGN-COV2 in order (see Figure 4). The first six are antibodies
under investigation in different phases as a treatment for COVID-19. Their high similarities to
REGN-COV2 make them strong candidates. Furthermore, nct04348877 and nct04344015 are
ClinicalTrials.gov identifiers for plasma-rich antibodies from patients recovered from COVID19.
5.1.3 Similarity Visualization
In Figure 5, we used T-SNE, a machine learning algorithm for data visualization, to
reduce the dimensionality of our word-embedding model by mapping the 200-dimensional data
in CDVec to two dimensions and visualizing the top 20 similarities between words (remdesivir,
fever, drugs, hygiene, avigan, covid19, atazanavir, regncov2, and dexamethasone).
Note the overlap between the similar words for remdesivir, avigan, and dexamethasone,
whereas the similar words for atazanavir are separate even though atazanavir is an antiviral
medicine like remdesivir and avigan.
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Figure 4. The Top 10 Similar Words for REGN-COV2

Figure 5. The Similar Words for Remdesivir, Fever, Drugs, Hygiene, Avigan, COVID-19,
Atazanavir, REGN-COV2, and Dexamethasone
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5.2 COVID-19 Vaccine Model
5.2.1 Verification
To verify our COVID-19 vaccine model (CVW2V) results, some general known words
and phrases related to COVID-19 vocabulary, such as SARS, vaccines, wearing a mask, and
dry cough, were chosen as seeds for the model to test the relationships between these words
and their similarities, depending on human judgment as shown in Table 4. For the first word,
SARS,

the

top

similar

words

are

sarscov,

sarscov1,

sars_coronavirus,

middle_east_respiratory_syndrome, sarscov2, severe_acute_respiratory_syndrome, mers_sars,
corona_virus, infec-tion, and pandemic. The first eight similarities are similar names for
COVID-19, whereas infection and pandemic are more general references related to COVID19. Similar words for vaccines are vaccine_candidates, inactivated_vaccines, mrna_vaccines,
immunization, live_attenuated, viral_vector, proteinbased_vaccines, subu-nit_vaccines,
rabies_vaccine, and hpv_vaccine. Most of these are types of vaccines. Wearing a mask, as a
protective means for COVID-19, has washing_hands, avoid_touching_face, wearing_gloves,
frequent_handwashing,

maintaining_social_distance,

staying_home,

face_covering,

personal_hygiene, avoiding_crowds, and cough_etiquette as the top 10 similarities, which are
also all protective measures against COVID-19. As a symptom of COVID-19, we chose dry
cough, which resulted in the top 10 similarities of shortness_breath, fever_cough, dyspnoea,
chills, runny_nose, chest_tightness, sore_throat, difficulty_breathing, myalgias, and
diarrhea_abdominal_pain. Thus, the similarities found are also symptoms of COVID-19.
5.2.2 Similarities for Some Vaccines
Vaccines are being developed with different technologies, some well-known and others
completely new for human vaccines, such as peptide and nucleic acid technologies.

33

Table 4.
The Top 10 First Similarities for SARS, Vaccines, Wearing a Mask, and Dry Cough

5.2.2.1 Whole Virus Vaccine
These are live-attenuated and inactivated vaccines. Live-attenuated vaccines use a
weakened (or attenuated) pathogen that causes disease and creates a strong and long-lasting
immune response. Because these vaccines are so close to the real natural infection, only one or
a maximum of two doses are needed to give lifetime immunity against the pathogen. These are
used to protect against rotavirus, yellow fever, and chickenpox [78]. The inactivated vaccines
use the dead version of the pathogen. Therefore, these vaccines do not provide an immunity
protection as strong as activated vaccines, so several doses are needed over time to get lasting
immunity. They are used to immunize against hepatitis A, flu, polio, and rabies [78].
Sinopharm and CoronaVac are examples of the inactivated virus vaccines for COVID-19.
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5.2.2.1.1 Sinopharm
Sinopharm, also known as BBIBP-CorV, was developed by the National
Pharmaceutical Group Corporation (CNPGC) in China, with 86% efficacy against the COVID19 infection [79]. As the most similar words for Sinopharm, CVW2V found sinovac,
coronavac, inactivated_vaccine_candidate, ad5ncov, sputnik_v, covaxin, co-dagenix,
adenovirusvectored,

adults_aged_18–59_years,

and

wibp_vaccine

(see

Figure

6).

Figure 6. The Similar Words for the Inactivated Virus Vaccines for
COVID-19, Sinopharm, and CoronaVac

Sinovac is a biopharmaceutical company in China that focuses on the research,
development, manufacturing, and commercialization of vaccines. This company developed the
CoronaVac inactivated virus COVID-19 vaccine. Ad5-nCoV, or Convidicea, was the first
novel coronavirus vaccine for COVID-19 in China and is a viral vector-based vaccine.
CoronaVac and Convidicea are under emergency use authorization status in China, Mexico,
Pakistan, Hungary, and Chile [80]. Sputnik-V (or Gam-COVID-Vac) is a viral vector vaccine
for COVID-19 developed by the Gamaleya Research Institute of Epidemiology and
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Microbiology in Russia. Registered on 11 August 2020 by the Russian Ministry of Health and
followed by an interim analysis of the trial was published in February 2021, the trial indicated
91.6% efficacy. Over a billion doses of that vaccine were requested by Russia, Argentina,
Belarus, Hungary, Serbia, and the United Arab Emirates for immediate distribution globally
[81]. Covaxin is another inactivated virus-based COVID-19 vaccine developed in India, by
Bharat Biotech in collaboration with the Indian Council of Medical Research. After the second
dose, it showed 81% intermediate effectiveness in preventing COVID-19 in those who had not
been previously infected [82]. Codagenix is a clinical-stage synthetic biology company that
uses programs to recode the genomes of viruses in order to create live-attenuated vaccines or
viruses that can be used to prevent viral infections. It generated COVI-VAC, a single-dose,
intranasal, live-attenuated vaccine against COVID-19. In Phase I, COVI-VAC showed good
results with respect to safety and protection after just one dose in the gold standard animal
model and is currently being evaluated in the clinical phase. COVI-VAC is designed to produce
immunity against all SARS-CoV-2 proteins to protect against a range of SARS-CoV-2 strains
[83]. Adenovirus vectored is a vector-based vaccine that adds a gene for the coronavirus
vaccine into a modified version of a chimpanzee adenovirus that can then enter human cells
but not replicate inside, so the vaccine can target the spike proteins that SARS-CoV-2 uses to
enter human cells [84]. Both the wibp_vaccine and BBIBP-CorV are in-activated virus
COVID-19 vaccines developed by Sinopharm [79].
5.2.2.1.2 CoronaVac
CoronaVac is an inactivated virus COVID-19 vaccine developed by the Chinese
company Sinovac Biotech. It has been in Phase III clinical trials in several countries. Because
it does not need to be frozen, it can be transported and refrigerated at 2–8 °C (36–46 °F), which
is the same temperature at which traditional flu vaccines are kept [85]. When CoronaVac was
used as a seed in our model, the top similar words were sinopharm, inactivated_vaccine,
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sinovac, picovacc, twodose_regimen, 4_weeks_apart, inovio, ino4800, scb2019, and arcov (see
Figure 6).
Picovacc is the previous name for CoronaVac, which requires a twodose_regimen and
4_weeks_apart, corresponds to the treatment plan that specifies the amount and schedule for
vaccination. Inovio, or ino4800, is a DNA vaccine, INO-4700, against MERS CoV that is
currently in preparation to initiate a Phase II vaccine trial [86]. The scb2019 subunit vaccine
candidate is developed by Clover Pharmaceuticals [87]. Arcov is the first mRNA vaccine in
China and may be ready for final stage trials overseas in May 2021[88].
5.2.2.2 RNA or mRNA Vaccines
mRNA vaccine development uses a new technology, based on proteins, to trigger an
immune response. They have several benefits compared to other types of vaccines, including
shorter manufacturing times and, because they do not contain a live virus, no risk of causing
disease in the person getting vaccinated. Moderna and Pfizer-BioNTech are examples of
mRNA vaccines for COVID-19. Under an Emergency Use Authorization (EUA) in December
2019, the FDA authorized emergency use of these vaccines to prevent or reduce the COVID19 infection in individuals of age 16 years and older. We used these two vaccines as seeds for
our model to search for similar candidate vaccines.
5.2.2.2.1 Moderna
The top similarities for Moderna are pfizer_biontech, mrna1273, mrnabased_vaccine,
encapsulated_mrna, johnson_johnson, astrazeneca, curevac, arcturus, gsk, and gx19 (see
Figure 7).
The mrna1273 similarity is another name for Moderna. CureVac COVID-19 is an
mRNA COVID-19 vaccine candidate developed by CureVac N.V. and the Coalition for
Epidemic Preparedness Innovations (CEPI), which is different from the current mRNA
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COVID-19 vaccines, Pfizer–BioNTech and Moderna. CureVac uses unmodified RNA, while
the other two use nucleoside-modified RNA. CureVac is in Phase III clinical trials, as of April
2021 [89]. Arcturus, or ARCT-02,1, is an mRNA COVID-19 vaccine candidate developed by
Arcturus Therapeutics and currently in Phase II [90]. Gsk, or VAT00002, is a protein subunit
COVID-19 vaccine candidate in Phase II and developed by Sanofi Pasteur and GSK [91]. The
gx19 DNA COVID-19 vaccine candidate is developed by Genexine and in Phase II status [92].

Figure 7. The Similar Words for Moderna and Pfizer-BioNTech as mRNA
Vaccines for COVID-19

5.2.2.2.2 Pfizer-BioNTech
The similar words found for Pfizer-BioNTech are astrazeneca, moderna, sputnik_v,
zydus_cadila, twodose, bbv152, adenovirusvectored, adults_aged_18–59_years, minor_side_
effects, and menacwy_vaccine (see Figure 7).
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An Indian multinational pharmaceutical company, zydus_cadila, develops a DNA
plasmid-based COVID-19 vaccine named ZyCoV-D, which is expected to get emergency use
authorization in May or June of 2022 [93]. BBV152, or Covaxin, is an inactivated virus-based
COVID-19 vaccine, which was developed by the Indian Council of Medical Research and
Bharat Biotech [94]. The MenACWY vaccine is a single injection given into the upper arm
that protects against four meningococcal bacteria strains that cause meningitis and blood
poisoning: A, C, W, and Y [95].
5.2.2.3 Viral Vector
Viral vector is a type of vaccine that uses a modified version of one virus as a vector.
This vector is a DNA molecule used as a vehicle to artificially carry foreign genetic material
into another cell. Even though it has two strange objects that enter the body, this type of vaccine
does not cause infection with either the virus used as the vector or the source of the antigen.
The genetic material it delivers does not integrate into a person’s genome [96]. Johnson &
Johnson’s Janssen and Oxford-AstraZeneca are examples of a viral vector-based COVID-19
vaccine.
5.2.2.3.1 Johnson & Johnson’s Janssen
Johnson & Johnson’s Janssen is a one dose viral-based COVID-19 vaccine developed
by Janssen Vaccines company. We used Johnson & Johnson’s Janssen as a seed to our model.
Pfizer, astrazeneca, nonreplicating_viral_vector, eli_lilly, merck, bgb_dxp593_beigene,
ad26covs1, sclamp, plantderived_vlp, and greffex are some similar words for this vaccine (see
Figure 8).
In addition, eli_lilly is an antibody-based treatment for COVID-19 with an Emergency
Use Authorization from the Food and Drug Administration [97]. Merck is a pharmaceutical
company working on developing an oral medication for COVID-19 and is in a Phase II clinical
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trial with promising early findings [98]. BGB-DXP593 is a neutralizing anti-body, or proteinbased therapy, under investigation for SARS-CoV-2 in a clinical trial for participants with
mild-to-moderate COVID-19 by BeiGene [99]; ad26covs1 is another name for Johnson &
Johnson’s Janssen vaccine. Sclamp, or V451, is a subunit-based COVID-19 vaccine developed
by the University of Queensland and the Australian pharmaceutical company CSL Limited and
is still in Phase I [100]. The plantderived_vlp vaccine is a different type of COVID-19 vaccine.
Instead of using a viral vector, it uses living plants as bioreactors to produce non-infectious
versions of viruses, called Virus-like Particles, or VLPs. This type of vaccine was developed
by the Canada-based biopharma Medicago and GlaxoSmithKline and is currently in Phase III
clinical trials [101]. Greffex is a vaccine based on an adenovirus viral vector, currently in a
pre-clinical phase and developed by Greffex, a genetic engineering company [102].

Figure 8. The Similar Words for Viral Vector-Based COVID-19 Vaccine, Johnson &
Johnson’s Janssen, and Oxford–AstraZeneca
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5.2.2.3.2 Oxford-AstraZeneca
Oxford-AstraZeneca is a viral vector-based COVID-19 vaccine developed by Oxford
University and AstraZeneca. According to CVW2V, interesting similar words for OxfordAstraZeneca are covishield, sinopharm, anges, ag0301covid19, vaxart, nvxcov2373,
simian_adenovirusvectored, TY027, and altimmune (see Figure 8).
The word covishield is another name for Oxford-AstraZeneca. Anges, or AG0302COVID-19, is a DNA candidate vaccine developed by AnGes Inc. in Japan and currently in
Phase II/III [103]. Vaxart is a nonreplicating viral vector oral vaccine platform for COVID-19
in Phase I [104]; and nvxcov2373 is a protein-based COVID-19 vaccine [105]. The
simian_adenovirusvectored vaccine is used as a vector in the vector-based vaccine instead of
the human adenovirus because of its advantages over the human adenovirus. TY027 is a
treatment for patients with COVID-19 to slow the progression of the disease and accelerate
recovery and has the potential to provide temporary protection against infection with SARSCoV-2 [106]. Altimmune is a single-dose viral vector COVID-19 vaccine that triggers a broad
immune response—neutralizing IgG, mucosal IgA, and T-cells—and is still in Phase I [107].
5.3 AM Model
5.3.1 Verification
We used some general keywords related to AM processes, parameters or alloys, such
as SLM (Selective Laser Melting), LPBF (Laser Powder Bed Fusion), hatch spacing, binder
saturation level, NiMn, and powder bed, as seeds to our AM model (AMW2V), to find their
most similar words. The results are shown in Table 5.
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Table 5.
The Similar Words for SLM, LPBF, Hatch Spacing, Binder Saturation Level,
NiMn, and Powder Bed
SLM

LPBF

hatch spacing

binder saturation level

NiMn

powder bed

lpbf

slm

Hatch_distance

zb56

coni

Powderbased

ebm

ebm

scan_spacing

layer_thickness_binder_
saturation

Mncu

pbf_processes

dmls

dmls

laser_spot_diameter

air_gap_raster_angle

feni

loose_powder

sebm

lbm

line_spacing

orientation_raster_angle+

fecu

build_platform

lmd

waam

008mm

air_gap_raster_width

nico

Recoating

alsi10
mg

ss316l

layer_thickness_kept
_constant

wc12_co

comn

Sls

ti64

scan_
strategy

laser_power_200w

zcast

Mnfe

unsintered_powder

ss316l

174_ph

131w

farzadi_m_solatihashjin

ni3fe

blown_powder

ti6al4v

in625

focal_position

exone_innovent

Cozn

Layering

alsi12

in718

stripe_width

beam_speed_hatch

feco

binder_jetting

For SLM, the most similar words were lpbf, ebm, dmls, sebm, lmd, alsi10mg, ti64,
ss316l, ti6al4v, and alsi12. The lpbf (laser powder bed fusion), ebm (Electron Beam Melting),
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dmls (Direct Metal Laser Sintering), sebm (Selective Electron Beam Melting), and lmd (Laser
Metal Deposition) are different AM techniques for SLM, whereas alsi10mg, ti64, ss316l,
ti6al4v, and alsi12 are popular alloys used in AM. AlSi10Mg is an aluminum alloy commonly
used in a powder form in the AM process because of its distinctive and convenient properties,
such as good hardness, low density, dynamic toughness, high corrosion resistance, and high
mechanical strength of the end parts [108]. Ti64 (or Ti-6Al-4V) is a well-known light titanium
alloy used in AM with characteristics that make it ideal for many high-performance
applications in medical, aerospace, and automotive areas. The high strength, hardness, high
plasticity, long fatigue life for the parts, low density, excellent corrosion resistance, and
superior biocompatibility with human tissue are the most important characteristics that make it
suitable for such applications [109]. SS316L (or 316L stainless steel) is another ideal alloy,
with a nickel and chromium content, manufactured by AM due to its properties, such as ease
of fabrication, biocompatibility, reasonable cost, sufficient mechanical strength, and corrosion
resistance [110]. The AlSi12 alloy is one of the most widely used metal powders in selective
laser melting (SLM), which is because of its relatively low price, low melting point, good
thermal properties, needed corrosion resistance, and high tensile strength with low specific
gravity [111].
The similar words for the lpbf (Laser Powder Bed Fusion) were slm, ebm, dmls, lbm,
waam, ss316l, scan_strategy, 174_ph, in625, and in718. The slm (Selective Laser Melting),
ebm (Electron Beam Melting), dmls (Direct Metal Laser Sintering), lbm (Laser Beam Melting),
and waam (Wire Arc Additive Manufacturing) are different techniques in AM. The ss316l and
174_ph alloys belong to the stainless-steel family of powders that have been used in AM
because of their optimal characteristics, whereas the in625 (or Inconel 625) and in718 (or
Inconel 718) alloys are members of the nickel alloy family of powders that AM has used to
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fabricate many parts for different applications, such as gas turbines for aerospace and energy
industries and ship building.
The words hatch_distance, scan_spacing, laser_spot_diameter, line_spacing, 008mm,
layer_thickness_kept_constant, laser_power_200w, 131w, focal_position, and stripe_width
were the most similar words for hatch spacing. The hatch spacing (or hatch distance) is one of
the AM process parameters, particularly laser and scan parameters. It is the separation of two
consecutive laser beams, measured by the distance from the center of one beam to the center
of the next beam.
Laser_spot_diameter, line_spacing, layer_thickness_kept_constant, laser_power_
200w, focal_position, and stripe_width are also parameters that influence the properties of parts
fabricated by AM processes [112], whereas 008mm and 131w are some values related to the
previous parameters.
For

the

binder

saturation

level,

the

most

similar

words

were

zb56,

layer_thickness_binder_saturation, air_gap_raster_angle, orientation_raster_angle, air_gap_
raster_width,

wc12_co,

zcast,

farzadi_m_solatihashjin,

exone_innovent,

and

beam_speed_hatch. The binder saturation level is the amount of binder deposited through the
printhead in the AM printing process. The layer_thickness, air_gap_raster_angle,
orientation_raster_angle, air_gap_raster_width, and beam_speed_hatch are some important
parameters in the printing process. The printing parameters are the settings and tuning that need
to be provided to the process in order to produce the AM product [113]. The words zcast and
zb56 are related to an AM process; zcast is a process developed by the Z Corporation that can
generate mould tools for the direct printing of complex moulds quickly and inexpensively with
a proprietary mould material (ZCast501), and zb56 is a binder in Zcast powder that gives
hardiness [114]. WC12Co is a powder consisting of tungsten carbide-cobalt that produces hard,
abrasive, and corrosion-resistant coatings, provides service in environments up to 900°F, and
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has been used in SLM as a powder to fabricate parts [115]. The name farzadi_m_solatihashjin
is given after the names of two professors, A. Farzadi and Mehran Solati-Hashjin, in the
Department of Materials and Metallurgical Engineering at the Amirkabir University of
Technology, Tehran. Their research areas of interest are biomaterials, 3D printing and
bioprinting, with a number of publications and citations. The ExOne Innovent is a 3D printer
made by the German manufacturer ExOne for industrial uses.
On the other hand, the similar words for NiMn (Nickel Manganese alloy) were coni
(Cobalt Nickel superalloy), mncu (Manganese-Copper alloy), feni (Iron–Nickel alloy), fecu
(Copper Iron alloy), nico (Cobalt-Nickel superalloy), comn (Cobalt Manganese alloy), mnfe
(Iron Manganese alloy), ni3fe (Nickel Iron alloy), cozn (Cobalt Zinc alloy), and feco (Iron
Cobalt alloy). All of these alloys have been used, sometimes in combinations, in AM
fabrication parts, especially in LPBF [116][117][118].
The words that had a vector similar to the powder bed vector were powderbased,
bf_processes, loose_powder, build_platform, recoating, sls (Selective Laser Sintering),
unsintered_powder, blown_powder, layering, and binder_jetting. Powder bed fusion
(powderbased or bf_processes) is a technique to fabricate parts in AM using lasers and the
powder of alloys. The terms loose_powder and unsintered_powder refer to the extra or unused
powder remaining from the powder bed fusion process, which could be reused in a new
fabrication. The word build_platform is the part of the printer where the object is printed. The
recoating is where a new layer of powder is spread on top of the printed layer in the PBF
process. The blown powder process (also known as Directed Energy Deposition (DED) or laser
cladding) involves inserting metal powder into a heat source—for example, a laser that melts
metal particles together when deposited [119]; binder_jetting is another type to fabricate parts
in AM that does not use heat during the materials fusing process.
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5.3.2 Similarities for Some Alloys
There are many produced alloys with wanted and required properties that have been
used in SLM, SLS, and MDSL. We are interested in Heusler alloys with Giant Magnetocaloric
Effect (GMCE) as observed in some of the Ni-Mn-X-based Heusler alloys. The MCE is a
property of some magnetic materials that, when heated up, they are placed in a magnetic field
(or magnetized) and cooled down when they are removed (or demagnetized). When the applied
magnetic field is increased, these materials transform from a low-symmetry martensitic phase
to a highly symmetric ferromagnetic (FM), austenitic phase. In some cases, such as with NiMn-based materials, a Giant Magnetocaloric Effect (GME) is exhibited, which is a
magnetocaloric effect much larger than MCE in other magnetic materials and can be exploited
for efficient cooling. Magnetic cooling could be a clean energy solution to replace conventional
vapor compression refrigeration in the future.
The net cooling effect of GMCE can be dominated by many factors, such as the
magneto-structural transition [120] and magnetic entropy changes. The magneto structural
phase transition is a coupling between structural and magnetic transitions that are exhibited by
magnetic materials [121]. The magnetic entropy change causes a temperature change of
magnetic materials in an adiabatic process under an external magnetic field.
The SLM process uses the powder of Ni-Mn-Ga to produce it in the form of melt-spun
precursors. The resulting material is capable of martensitic transformation and has a uniform
chemical composition. This alloy shows a typical plate-like martensitic microstructure. Apart
from martensite plates, the microstructure contains a high density of stacking faults and
dislocations. From the magnetic susceptibility and magnetization measurements, it turns out
that the ternary Ni-Mn-Ga shows a stronger magnetic response than the other alloys [122]. In
order to search for more Ni-Mn-based Heusler alloys candidates, we used main words, such as
giant magnetocaloric effect, Ni-Mn-based Heusler alloys, magnetic entropy change, and
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magneto structural transition as seeds to our model to find some new candidate alloys. We
queried our model, AMW2V, to find the most similar words for these key words. Because this
resulted in many different alloys, properties, and parameters, we decided to tighten the result
by making the key words more specific. We studied some intersections between the word
similarities, looking for alloys that occur simultaneously within the similar words for both
“giant magnetocaloric effect” and “Ni-Mn-based Heusler alloys.” As shown in Figure 9,
mnfepge_compounds, ni-mn-in-co, fe49rh51, nicomnsn, mncoge, ni50mn35in15_heusler,
nimnsn, ni43mn46sn11, lafesi13based, mnas1-xsbx, gd5ge2si2, mnassb, tb5si2ge2, erco2,
mnnige, mnfe2psi, gd5si2ge2, nazn13type, mnfep1xasx, ni-co-mn-in, mnfepsi, ni-co-mn-sb,
and nimnz are in the intersection of similarities considered. This introduces them as predicted
candidates to be produced in LBPF processes.

Figure 9. The Intersection of the Similarities for Both “Giant Magnetocaloric Effect”
and “Ni-Mn-Based Heusler Alloys”
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Figure 10. The Intersection of the Similarities for Both Magnetic Entropy Change
and Ni-Mn-Based Heusler Alloys
Some other intersections between the similarities were obtained, such as the
intersection of the similar words between “magnetic entropy change” and “nimnbased heusler
alloys” )see Figure 10), and the intersection of the similar words between “magnetic entropy
change” and “giant magnetocaloric effect” )see Figure 11).

Figure 11. The Intersection of the Similarities for Both Magnetic Entropy
Change and Giant Magnetocaloric Effect
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Figure 12. The Intersection Between Ni-Mn-Based Heusler Alloys, Magnetic
Entropy Changes, GMCE, and Magnetostructural Transition

To find the top candidate alloys, the intersection between the most dominant factors in
the GMCE was obtained (see Figure 12). Because mnfep045as055, erco2, ni43mn46sn11,
mncogebased, gd5ge2si2, mn3gac, and ni50mn34in16 are the alloys that occur within the
similar words for Ni-Mn-based Heusler alloys, magnetic entropy changes, GMCE, and
magnetostructural transition, they could be considered as top candidates to be produced in
LPBF processes. Alloy MnFeP045As055, as compared to well-known magnetic alloys, such
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as gadolinium alloy, is thought to be a promising magnetic material with improved magnetic
properties [123]. ErCo2 shows a large magnetocaloric effect, suggesting a high potential for a
working substance of magnetic refrigeration at 30-50 K [124]. In addition, ni43mn46sn11 and
ni50mn34in16 are alloys with a behavior that allows the magnetic-field-driven transition from
martensitic phase with low magnetization to austenite with high magnetization, which results
in a GMCE property [125]. MnCoGe-based alloys have a strong interplay between structure
and magnetism, which results in the exhibited GME [126]. We also found that gd5ge2si2 is a
very good alloy for application as an active regenerator material in room temperature magnetic
refrigerators because of the GME with a transition temperature at around 276 K [127]. All of
these alloys have not been produced by LPBF processes (as of the date of writing). Thus, they
may be good candidate materials with GMCE to be produced by LPBF. However, the usage of
As and Gd would be a significant concern in terms of the material's safety [128][129][130].
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CHAPTER 6
CONCLUSIONS AND FUTURE WORK
6.1 Conclusions
In this work, we trained several unsupervised learning models using word embeddings
and the Word2Vec algorithm with information from the COVID-19 literature, especially
concerning drugs and vaccines, and with Additive Manufacturing literature focusing on LPBF
processes, GMCE, and Ni-Mn-based Huesler alloys.
To answer the research question—“What candidate drugs can be obtained from word
embeddings using Word2Vec algorithms to treat COVID-19?”—we trained an unsupervised
learning model (CDVec) using word embedding and the Word2Vec algorithm to capture latent
knowledge about COVID-19 treatments from the most recent literature, while focusing on
drugs, biomedicine, medication, antibodies, immunity, immunology, and vaccines. Without
any prior explicitly inserted knowledge about drugs, treatment, or biomedical information
about COVID-19, our model CDVec was able to indicate some candidate drugs for COVID19. Depending on the co-occurrence of the words, as similar words that occur together tend to
have a similar context, we used approved drugs, like remdesivir, or most promising drugs, like
avigan, atazanavir, dexamethasone, and REGN-COV2, as seeds to our model to find the most
similar drugs. As a result, CDVec suggests many possible candidate drugs for clinical
investigation and supports other ones in different testing phases for approval, according to their
high similarity with currently approved and most promising treatments [32].
In addition to our work in on drug discovery using Word2vec for COVID-19
treatments, for the research question—“What candidate vaccines can be obtained from word
embeddings using Word2Vec algorithms to reduce COVID-19 cases?”—we trained an
unsupervised word embedding model (CVW2V) to search for potential candidate vaccines in
the COVID-19 literature, according to their similarities with authorized or most promising
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existing ones. These studies rely on the property that words sharing similar surrounding words
are semantically close. After verifying CVW2V with the terms SARS, vaccines, wearing a
mask, and dry cough as general words and their similarities, CVW2V was provided with
currently authorized vaccine names, such as Sinopharm and CoronaVac, as inactivated whole
virus-based vaccines, Moderna and Pfizer-BioNTech as mRNA vaccines, and Johnson &
Johnson’s Janssen and Oxford–AstraZeneca as viral vector-based COVID-19 vaccines. As a
result, without any explicitly inserted knowledge about COVID-19 or vaccines or any supervision on the words or objects and their meanings, the CVW2V model was able to suggest
several potential target vaccines for clinical investigation and support other ones in different
clinical experimental phases, according to their high similarity with currently authorized and
most promising vaccines [33].
In order to answer the research question—“What new knowledge on materials and
properties that are similar to those of known materials and properties can be extracted to
improve AM processes?”—we trained an unsupervised word-embedding model (AMW2V),
using Word2Vec primarily focused on Ni-Mn-based alloys, SLM, SLS, and DML, in the years
from 2012 to 2022 from Science Direct at Elsevier, to search for candidate alloys with GMCE
to be produced with LPBF processes. AMW2V predicted some candidates, such as
mnfep045as055,

erco2,

ni43mn46sn11,

mncogebased,

gd5ge2si2,

mn3gac,

and

ni50mn34in16, according to their similarities with given Ni-Mn-based Huesler alloys
exhibiting GMCE properties based on magnetic entropy changes and magnetostructural
transition.
6.2. Future Work
For future work in the COVID-19 field, we are planning to obtain more hidden
knowledge from the updated published literature about, for example, COVID-19 preexisting
conditions, healthcare, vaccine deniers, and possible new strains of COVID-19.

52

On the materials science side, our research supports a direction of producing candidate
alloys using LPBF with optimum process parameter combinations, including laser power,
scanning speed, hatch spacing, and layer thickness, allowing manufacturers to accurately
produce parts with complex shapes and intricate features from the candidate alloys.
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